Combining lurbinectedin with anticoagulants may pose specific risks. Lurbinectedin, a chemotherapy drug used to treat certain types of cancer, can increase the risk of bleeding due to its impact on platelet levels and coagulation factors. Anticoagulants, on the other hand, are medications that help prevent blood clots. When these two types of medications are combined, there is a potential for an increased risk of bleeding complications. It is crucial for healthcare providers to closely monitor patients who are receiving both lurbinectedin and anticoagulants to manage this risk effectively [1][2][3].

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2016-01032
[3] https://www.mayoclinic.org/drugs-supplements/nirmatrelvir-and-ritonavir-oral-route/precautions/drg-20528231?p=1